Depression is common in many patients hospitalized with coronary artery disease (CAD) and is associated with increased risks of cardiovascular morbidity and mortality. However, few studies have assessed the effectiveness of interventions to treat depression in patients with CAD. In this issue of JAMA, Lespérance and colleaguesArticle report results of a 12-week randomized trial, which assessed the efficacy of citalopram, a selective serotonin reuptake inhibitor (SSRI), vs placebo and interpersonal psychotherapy added to supportive, nonpsychotherapeutic clinical management vs clinical management alone to reduce symptoms of depression in patients with CAD and major depressive disorder. The investigators found that citalopram was superior to placebo when administered with weekly clinical management in reducing self-reported and clinically assessed symptoms of depression. There was no evidence that the addition of interpersonal therapy to clinical management was beneficial. In an editorial, Glassman and BiggerArticle discuss the efficacy and safety of 2 SSRIs—sertraline and citalopram—for the treatment of depression in patients with coronary heart disease.
This Week in JAMA . JAMA. 2007;297(4):337. doi:10.1001/jama.297.4.337